|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0834 USD | -5.17% |
|
+15.33% | -10.79% |
Enzon Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported revenue was USD 0.026 million compared to USD 0.701 million a year ago. Net loss was USD 0.186 million compared to USD 0.469 million a year ago.
Basic loss per share from continuing operations was USD 0.02 compared to USD 0.03 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -10.79% | 6.19M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.75% | 22.15B | |
| -17.37% | 21.02B | |
| -9.26% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
ENZON PHARMACEUTICALS, INC. 
